-
Patent Agency Ranking
公开(公告)号：KR1019950024831A
公开(公告)日：1995-09-15
申请号：KR1019940003495
申请日：1994-02-25
Applicant: 한국과학기술연구원
IPC: B21D53/88
Abstract: 본 발명은 복합재료 샤프트와 금속샤프트를 접착제나 동시경화법에 의하여 접착하여 접착상태의 신뢰성을 높이고 토크전달능력이 양호하도록 하는 것으로 종래에 고가비용으로도 소음과 진동을 해소치 못한점과 접착상태의 신뢰성과 토크전달능력등에서 발생하는 문제점을 해결하기 위하여 복합재료 샤프트와 금속샤프트를 사용하여 이중겹치기 방법으로 연결하고 접착부에 열박음한 후 용접한 것과 동시경화법 또는 접착제로 별개로 제조되는 복합재료 샤프트와 금속샤프트를 접착하여 성능이 우수한 일체형 복합재료 드라이브 샤프트와 그 제조방법을 제공하는 것이다.
-
公开(公告)号：KR1020110020387A
公开(公告)日：2011-03-03
申请号：KR1020090077979
申请日：2009-08-24
Applicant: 한국과학기술연구원
IPC: A61K31/465 , A61K31/7105 , A61P25/08 , A61P25/28
CPC classification number: A61K31/00 , A61K31/185 , A61K31/196 , A61K31/455 , A61K31/7105 , A61K31/713 , A61K38/043 , A61K38/08 , G01N33/9426 , G01N2500/10
Abstract: PURPOSE: A GABA(gamma-aminobutyric acid) release inhibitor containing bestrophin 1 channel inhibitor is provided to enable effective and various treatment for GABA-associated disease symptom. CONSTITUTION: A composition for preventing or treating diseases or symptom due to GABA excessive release contains bestrophin 1 channel inhibitor as an active ingredient. The composition suppresses GABA release in the bovine cerebellum. The bestrophin 1 channel inhibitor is an antisense RNA or shRNA of a nucleotide sequence encoding an anion channel blocker and bestrophin 1 channel. The anion channel blocker is niflumic acid, 5-nitro-2(3-phenylpropylamino)-bazoic acid(NPPB) or 4,4'-diisothiocyanatostylbene-2,2'-disulfonic acid(DIDS). The nucleotide sequence encoding the bestrophin 1 channel is a sequence of sequence number 1 or 2. A composition for preventing or treating diseases due to GABA deficiency contains a bestrophin 1 channel activator as an active ingredient. The activator is a peptide TFLLR and Bradykinin.
Abstract translation: 目的：提供含有bestrophin 1通道抑制剂的GABA（γ-氨基丁酸）释放抑制剂，以有效和各种治疗GABA相关疾病症状。 构成：用于预防或治疗由于GABA过度释放引起的疾病或症状的组合物，含有bestrophin 1通道抑制剂作为活性成分。 该组合物抑制牛小脑中的GABA释放。 bestrophin 1通道抑制剂是编码阴离子通道阻断剂和bestrophin 1通道的核苷酸序列的反义RNA或shRNA。 阴离子通道阻断剂是尼氟酸，5-硝基-2（3-苯基丙基氨基） - 二羧酸（NPPB）或4,4'-二异硫氰基脂肪基-22'-二磺酸（DIDS）。 编码bestrophin 1通道的核苷酸序列是序列号1或2的序列。用于预防或治疗由于GABA缺陷引起的疾病的组合物含有作为活性成分的bestrophin 1通道激活剂。 活化剂是肽TFLLR和缓激肽。
-
公开(公告)号：KR1019960005822B1
公开(公告)日：1996-05-01
申请号：KR1019940003495
申请日：1994-02-25
Applicant: 한국과학기술연구원
IPC: B21D53/88
Abstract: This drive shaft manufacturing method is designed to improve the state of adhesion and the efficiency of dynamic torque transfer. To achieve the purpose, the adhesive is used to connect composite material shaft to metal shaft by double folding method, joint the connection portion by line and weld it, grind the surface of two shafts with #80 sand paper, erode it in 10% nitiric acid and 90% ethanol solution for 5 min. then paste them by 0.1 - 1.0 mm deep adhesive, prepare two shafts each, or paste them by simultaneous hardening process, pose the composite material shaft at inner side, combine metal shaft at outside by adhesive or simultaneous hardening process, roll mandrel with polymer film and composite material, then pull out the mandrel again, and apply pressure on the internal film, hardening composite material by the simultaneous hardening process of two shafts.
Abstract translation: 该驱动轴制造方法旨在改善粘合状态和动态转矩传递的效率。 为了达到目的，粘合剂用于通过双折叠方式将复合材料轴连接到金属轴上，将连接部分接合并焊接，用＃80砂纸研磨两个轴的表面，将其以10％的腈纶 酸和90％乙醇溶液5分钟。 然后将其粘贴0.1〜1.0mm深的粘合剂，准备两个轴，或通过同时硬化处理粘贴，将复合材料轴置于内侧，通过粘合或同时硬化处理将金属轴与外部结合在一起，辊心与聚合物膜 和复合材料，然后再次拉出心轴，并对内膜施加压力，通过两个轴的同时硬化过程硬化复合材料。
-
公开(公告)号：KR101154538B1
公开(公告)日：2012-06-13
申请号：KR1020090077979
申请日：2009-08-24
Applicant: 한국과학기술연구원
IPC: A61K31/465 , A61K31/7105 , A61P25/08 , A61P25/28
CPC classification number: A61K31/00 , A61K31/185 , A61K31/196 , A61K31/455 , A61K31/7105 , A61K31/713 , A61K38/043 , A61K38/08 , G01N33/9426 , G01N2500/10
Abstract: A GABA (gamma-aminobutyric acid) release-inhibiting agent in the cerebellum and a composition for treating pathological symptoms caused by over-release of GABA in the cerebellum, each comprising a Bestrophin 1(Best1) channel inhibitor as an active ingredient; a GABA release-promoting agent in the cerebellum and a composition for treating pathological symptoms caused by the deficit of GABA in the cerebellum, each comprising a Best1 channel activator as an active ingredient; and a method for screening a GABA release-regulating agent in the cerebellum, which uses Best1 channel as target, are provided.
-
-
-
-
Search Results
5
records
(took 0.019 seconds)
